
HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SUTENT safely and effectively. See full prescribing information for SUTENT.

SUTENT[®] (sunitinib malate) capsules, for oral use Initial U.S. Approval: 2006

WARNING: HEPATOTOXICITY

See full prescribing information for complete boxed warning.

Hepatotoxicity has been observed in clinical trials and postmarketing experience. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended *[see Warnings and Precautions (5.1)]*.

----- RECENT MAJOR CHANGES ------

Boxed Warning	11/2017
Indications and Usage, Adjuvant Treatment of Renal Cell Carcinoma (RCC) (1.3)	11/2017
Dosage and Administration, Recommended Dose for Adjuvant Treatment of RCC (2.2)	11/2017
Dosage and Administration, Dose Modification (2.4)	11/2017
Warnings and Precautions (5)	11/2017

INDICATIONS AND USAGE SUTENT is a kinase inhibitor indicated for: the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.

- the treatment of advanced renal cell carcinoma (RCC). (1.2)
- the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. (1.3)
- the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. (1.4)

----- DOSAGE AND ADMINISTRATION -----

GIST and Advanced RCC:

• 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off. (2.1)

Adjuvant RCC:

(1.1)

• 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off for nine 6-week cycles. (2.2)

pNET:

• 37.5 mg orally once daily, with or without food, continuously without a scheduled off-treatment period. (2.3)

Dose Modification:

• Dose interruptions and/or dose adjustments of 12.5 mg recommended based on individual safety and tolerability. (2.4)

----- DOSAGE FORMS AND STRENGTHS

• Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg (3)

----- CONTRAINDICATIONS ------

- None (4)
- ------ WARNINGS AND PRECAUTIONS ------
- Hepatotoxicity, including fatal liver failure, has been observed. Monitor liver function tests before initiation of treatment, during each cycle of treatment, and as clinically indicated. Interrupt SUTENT for Grade 3 or 4 drug-related hepatic adverse reactions and discontinue if there is no resolution. Do not restart SUTENT if patients experience severe changes in liver function tests or have signs and symptoms of liver failure. (5.1)
- Cardiovascular events including myocardial ischemia, myocardial infarction, left ventricular ejection fraction declines to

below the lower limit of normal and cardiac failure including death have occurred. Monitor patients for signs and symptoms of congestive heart failure. Discontinue SUTENT for clinical manifestations of congestive heart failure. (5.2)

- Prolonged QT intervals and Torsade de Pointes have been observed. Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. (5.3)
- Hypertension may occur. Monitor blood pressure and treat as needed. (5.4)
- Hemorrhagic events, including tumor-related hemorrhage, and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. (5.5)
- Cases of Tumor Lysis Syndrome (TLS) (some fatal) have been reported primarily in patients with RCC and GIST with high tumor burden. Monitor these patients closely and treat as clinically indicated. (5.6)
- Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue SUTENT in patients developing TMA. (5.7)
- Proteinuria, including renal failure or a fatal outcome, has occurred. Monitor urine protein. Interrupt treatment for 24hour urine protein ≥3 grams. Discontinue for repeat episodes of protein ≥3 grams despite dose reductions or nephrotic syndrome. (5.8)
- Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue SUTENT if these events occur. (5.9)
- Thyroid dysfunction may occur. Patients with signs and/or symptoms suggestive of hypothyroidism or hyperthyroidism should have laboratory monitoring of thyroid function performed and be treated as per standard medical practice. (5.10)
- Hypoglycemia may occur. Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (5.11)
- Osteonecrosis of the jaw has been reported. Consider preventive dentistry prior to treatment with SUTENT. If possible, avoid invasive dental procedures, particularly in patients receiving intravenous bisphosphonate therapy. (5.12)
- Wound Healing: Impaired wound healing has occurred with SUTENT. Temporary interruption of therapy with SUTENT is recommended in patients undergoing major surgical procedures. (5.13)
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. (5.14, 8.1, 8.3)
- ------ ADVERSE REACTIONS ------
- The most common adverse reactions (>25%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

----- DRUG INTERACTIONS

- CYP3A4 Inhibitors: Consider dose reduction of SUTENT when administered with strong CYP3A4 inhibitors. (7.1)
- CYP3A4 Inducers: Consider dose increase of SUTENT when administered with CYP3A4 inducers. (7.2)

------ USE IN SPECIFIC POPULATIONS ------

• Lactation: Advise women not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 11/2017

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: HEPATOTOXICITY 1 INDICATIONS AND USAGE

- 1.1 Gastrointestinal Stromal Tumor (GIST)
- 1.2 Advanced Renal Cell Carcinoma (RCC)
- 1.3 Adjuvant Treatment of Renal Cell Carcinoma (RCC)
- 1.4 Advanced Pancreatic Neuroendocrine Tumors (pNET)

2 DOSAGE AND ADMINISTRATION

- 2.1 Recommended Dose for GIST and Advanced RCC
- 2.2 Recommended Dose for Adjuvant Treatment of RCC
- 2.3 Recommended Dose for pNET
- 2.4 Dose Modification

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Hepatotoxicity
- 5.2 Cardiovascular Events
- 5.3 QT Interval Prolongation and Torsade de Pointes
- 5.4 Hypertension
- 5.5 Hemorrhagic Events and Viscus Perforation
- 5.6 Tumor Lysis Syndrome (TLS)
- 5.7 Thrombotic Microangiopathy
- 5.8 Proteinuria
- 5.9 Dermatologic Toxicities
- 5.10 Thyroid Dysfunction
- 5.11 Hypoglycemia
- 5.12 Osteonecrosis of the Jaw (ONJ)
- 5.13 Wound Healing

5.14 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 CYP3A4 Inhibitors
- 7.2 CYP3A4 Inducers
- 7.3 In Vitro Studies of CYP Inhibition and Induction

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8.7 Renal Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

12.4 Cardiac Electrophysiology

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Gastrointestinal Stromal Tumor
- 14.2 Renal Cell Carcinoma
- 14.3 Pancreatic Neuroendocrine Tumors

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

WARNING: HEPATOTOXICITY

Hepatotoxicity has been observed in clinical trials and postmarketing experience. Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended *[see Warnings and Precautions* (5.1)].

1 INDICATIONS AND USAGE

1.1 Gas trointes tinal Stromal Tumor (GIST)

SUTENT is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

1.2 Advanced Renal Cell Carcinoma (RCC)

SUTENT is indicated for the treatment of advanced renal cell carcinoma.

1.3 Adjuvant Treatment of Renal Cell Carcinoma (RCC)

SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.

1.4 Advanced Pancreatic Neuroendocrine Tumors (pNET)

SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose for GIST and Advanced RCC

The recommended dose of SUTENT for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is one 50 mg oral dose taken once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2). SUTENT may be taken with or without food.

2.2 Recommended Dose for Adjuvant Treatment of RCC

The recommended dose of SUTENT for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. SUTENT may be taken with or without food.

2.3 Recommended Dose for pNET

The recommended dose of SUTENT for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily continuously without a scheduled off-treatment period. SUTENT may be taken with or without food.

2.4 Dose Modification

Dose interruption and/or dose modification in 12.5 mg increments or decrements is recommended based on individual safety and tolerability. The maximum dose administered in the pNET study was 50 mg daily. In the adjuvant RCC study, the minimum dose administered was 37.5 mg.

Strong CYP3A4 inhibitors such as ketoconazole may **increase** sunitinib plasma concentrations. Selection of an alternate concomitant medication with no or minimal enzyme inhibition potential is recommended. A dose reduction for SUTENT to a minimum of 37.5 mg (GIST and RCC) or 25 mg (pNET) daily should be considered if SUTENT must be coadministered with a strong CYP3A4 inhibitor *[see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]*.

CYP3A4 inducers such as rifampin may **decrease** sunitinib plasma concentrations. Selection of an alternate concomitant medication with no or minimal enzyme induction potential is recommended. A dose increase for SUTENT to a maximum of 87.5 mg (GIST and RCC) or 62.5 mg (pNET) daily should be considered if SUTENT must be coadministered with a CYP3A4 inducer. If dose is increased, the patient should be monitored carefully for toxicity [*see Drug Interactions (7.2) and Clinical Pharmacology (12.3)*].

3 DOSAGE FORMS AND STRENGTHS

12.5 mg capsules

Hard gelatin capsule with orange cap and orange body, printed with white ink "Pfizer" on the cap and "STN 12.5 mg" on the body.

25 mg capsules

Hard gelatin capsule with caramel cap and orange body, printed with white ink "Pfizer" on the cap and "STN 25 mg" on the body.

37.5 mg capsules

Hard gelatin capsule with yellow cap and yellow body, printed with black ink "Pfizer" on the cap and "STN 37.5 mg" on the body.

50 mg capsules

Hard gelatin capsule with caramel top and caramel body, printed with white ink "Pfizer" on the cap and "STN 50 mg" on the body.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Hepatotoxicity

SUTENT can cause severe hepatotoxicity, resulting in liver failure or death. Liver failure occurred at an incidence of <1% in clinical trials. Liver failure signs include jaundice, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) before initiation of treatment, during each cycle of treatment, and as clinically indicated. Interrupt SUTENT for Grade 3 or 4 drug-related hepatic adverse reactions and discontinue if there is no resolution. Do not restart SUTENT if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.

Safety in patients with ALT or AST >2.5 × upper limit of normal (ULN) or, if due to liver metastases, >5.0 × ULN has not been established.

5.2 Cardiovas cular Events

Discontinue SUTENT in the presence of clinical manifestations of congestive heart failure (CHF).

Interrupt SUTENT and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of >20% but <50% below baseline or below the lower limit of normal if baseline ejection fraction is not obtained.

In patients without cardiac risk factors a baseline evaluation of ejection fraction should be considered. Carefully monitor patients for clinical signs and symptoms of CHF while receiving SUTENT. Baseline and periodic evaluations of left ventricular ejection fraction (LVEF) should also be considered while these patients are receiving SUTENT.

Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported.

In patients treated with SUTENT (N=7527) for GIST, advanced RCC, adjuvant treatment of RCC and pNET, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients.

In the adjuvant treatment of RCC study, 11 patients in each arm experienced a decreased ejection fraction meeting Grade 2 CTCAE criteria (LVEF 40–50% and a 10–19% decrease from baseline). No patients had a Grade 3–4 decrease in ejection fraction. The ejection fractions of three patients in the SUTENT arm and 2 patients in the placebo arm did not return to \geq 50% or baseline by the time of last measurement. No patients who received SUTENT were diagnosed with CHF.

Patients who presented with cardiac events within 12 months prior to SUTENT administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from SUTENT clinical studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing drug-related left ventricular dysfunction.

5.3 QT Interval Prolongation and Torsade de Pointes

SUTENT can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes has been observed in <0.1% of SUTENT-exposed patients.

Monitor patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. When using SUTENT, periodic monitoring with on-treatment electrocardiograms and electrolytes (magnesium, potassium) should be considered. Concomitant treatment with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations and dose reduction of SUTENT should be considered [see Dosage and Administration (2.4)].

5.4 Hypertension

Monitor patients for hypertension and treat as needed with standard antihypertensive therapy. In cases of severe hypertension, temporary suspension of SUTENT is recommended until hypertension is controlled.

In patients treated with SUTENT (N=7527) in GIST, advanced RCC, adjuvant treatment of RCC and pNET, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2% of patients.

5.5 Hemorrhagic Events and Viscus Perforation

Hemorrhagic events reported through postmarketing experience, some of which were fatal, have included GI, respiratory, tumor, urinary tract, and brain hemorrhages. In patients treated with SUTENT (N=7527) for GIST, advanced RCC, adjuvant treatment of RCC and pNET, 30% of patients experienced hemorrhagic events, and 4.2% of patients experienced a Grade 3 or 4 event. Epistaxis was the most common hemorrhagic adverse reaction and gastrointestinal hemorrhage was the most common Grade \geq 3 event.

Tumor-related hemorrhage has been observed in patients treated with SUTENT. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Cases of pulmonary hemorrhage, some with a fatal outcome, have been observed in clinical trials and have been reported in postmarketing experience in patients treated with SUTENT for metastatic RCC, GIST, and metastatic lung cancer. SUTENT is not approved for use in patients with lung cancer. Clinical assessment of hemorrhagic events should include serial complete blood counts (CBCs) and physical examinations.

Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with SUTENT.

5.6 Tumor Lysis Syndrome (TLS)

Cases of TLS, some fatal, occurred in clinical trials and have been reported in postmarketing experience, primarily in patients with RCC or GIST treated with SUTENT. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients closely and treat as clinically indicated.

5.7 Thrombotic Microangiopathy

Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. Discontinue SUTENT in patients developing TMA. Reversal of the effects of TMA has been observed after treatment was discontinued.

5.8 Proteinuria

Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt SUTENT and dose reduce for 24-hour urine protein \geq 3 grams. Discontinue SUTENT for patients with nephrotic syndrome or repeat episodes of urine protein \geq 3 grams despite dose reductions. The safety of continued SUTENT treatment in patients with moderate to severe proteinuria has not been systematically evaluated.

5.9 Dermatologic Toxicities

Severe cutaneous reactions have been reported, including cases of erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. If signs or symptoms of EM, SJS, or TEN (e.g., progressive skin rash often with blisters or mucosal lesions) are present, discontinue SUTENT treatment. If a diagnosis of SJS or TEN is suspected, SUTENT treatment must not be re-started.

Necrotizing fasciitis, including fatal cases, has been reported in patients treated with SUTENT, including of the perineum and secondary to fistula formation. Discontinue SUTENT in patients who develop necrotizing fasciitis.

5.10 Thyroid Dysfunction

Baseline laboratory measurement of thyroid function is recommended and patients with hypothyroidism or hyperthyroidism should be treated as per standard medical practice prior to the start of SUTENT treatment. All patients should be observed closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, while on SUTENT treatment. Patients with signs and/or symptoms suggestive of thyroid dysfunction should have laboratory monitoring of thyroid function performed and be treated as per standard medical practice.

Cases of hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and

through postmarketing experience.

5.11 Hypoglycemia

SUTENT can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with SUTENT for advanced RCC and GIST and in approximately 10% of the patients treated with SUTENT for pNET. In the adjuvant treatment of RCC study, no patients on SUTENT experienced hypoglycemia. For patients being treated with SUTENT for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in diabetic patients. Check blood glucose levels regularly during and after discontinuation of treatment with SUTENT. Assess if antidiabetic drug dosage needs to be adjusted to minimize the risk of hypoglycemia.

5.12 Osteonecrosis of the Jaw (ONJ)

ONJ has been observed in clinical trials and has been reported in postmarketing experience in patients treated with SUTENT. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease, may increase the risk of osteonecrosis of the jaw. Consider preventive dentistry prior to treatment with SUTENT. If possible, avoid invasive dental procedures while on SUTENT treatment, particularly in patients receiving intravenous bisphosphonate therapy.

5.13 Wound Healing

Cases of impaired wound healing have been reported during SUTENT therapy. Temporary interruption of SUTENT therapy is recommended for precautionary reasons in patients undergoing major surgical procedures. There is limited clinical experience regarding the timing of reinitiation of therapy following major surgical intervention. Therefore, the decision to resume SUTENT therapy following a major surgical intervention should be based upon clinical judgment of recovery from surgery.

5.14 Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, SUTENT can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the clinical systemic exposure (AUC) at the recommended daily doses (RDD) of 50 mg/day, respectively.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with SUTENT and for 4 weeks following the final dose [see *Clinical Pharmacology* (12.1) and Use in Specific Populations (8.1, 8.3)].

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the labeling.

- Hepatotoxicity [see Warnings and Precautions (5.1)]
- Cardiovascular Events [see Warnings and Precautions (5.2)]
- QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions (5.3)]
- Hypertension [see Warnings and Precautions (5.4)]
- Hemorrhagic Events [see Warnings and Precautions (5.5)]
- Tumor Lysis Syndrome (TLS) [see Warnings and Precautions (5.6)]
- Thrombotic Microangiopathy [see Warnings and Precautions (5.7)]
- Proteinuria [see Warnings and Precautions (5.8)]
- Dermatologic Toxicities [see Warnings and Precautions (5.9)]
- Thyroid Dysfunction [see Warnings and Precautions (5.10)]
- Hypoglycemia [see Warnings and Precautions (5.11)]

- Osteonecrosis of the Jaw (ONJ) [see Warnings and Precautions (5.12)]
- Wound Healing [see Warnings and Precautions (5.13)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described in the Warnings and Precautions reflect exposure to SUTENT (N = 7527) in GIST, advanced RCC, adjuvant treatment of RCC, and pNET [see Warnings and Precautions (5.1, 5.13)]. In this database, the most common adverse reactions (\geq 25%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia.

The data below reflect exposure to SUTENT in 966 patients who participated in the treatment phase of randomized trials of GIST (n=202), advanced RCC (n=375), adjuvant treatment of RCC (n=306), and pNET (n=83) [see Clinical Studies (14.1, 14.2, 14.3)].

Gastrointestinal Stromal Tumor (GIST)

The safety of SUTENT was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received SUTENT 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102).

Median duration of blinded study treatment was 2 cycles for patients on SUTENT (mean: 3.0; range: 1–9) and 1 cycle (mean; 1.8; range: 1–6) for patients on placebo at the time of the interim analysis. Dose reductions occurred in 23 patients (11%) on SUTENT and none on placebo. Dose interruptions occurred in 59 patients (29%) on SUTENT and 31 patients (30%) on placebo. The rates of treatment-emergent, nonfatal adverse reactions resulting in permanent discontinuation were 7% and 6% in the SUTENT and placebo groups, respectively.

Most treatment-emergent adverse reactions in both study arms were Grade 1 or 2 in severity. Grade 3 or 4 treatment-emergent adverse reactions were reported in 56% versus 51% of patients on SUTENT versus placebo, respectively, in the double-blind treatment phase of the trial. Table 1 compares the incidence of common (\geq 10%) treatment-emergent adverse reactions for patients receiving SUTENT and reported more commonly in patients receiving SUTENT than in patients receiving placebo.

	GIST			
	SUTENT	Г (N=202)	Placebo	(N=102)
	All Grades	Grade 3–4	All Grades	Grade 3–4
Adverse Reaction	%	%	%	%
Any Adverse Reaction	94	56	97	51
Gas trointes tinal				
Diarrhea	40	4	27	0
Mucositis/stomatitis	29	1	18	2
Constipation	20	0	14	2
Cardiac				
Hypertension	15	4	11	0
Dermatology				
Skin discoloration	30	0	23	0

Table 1. Adverse Reactions Reported in Study 1 in ≥10% of GIST Patients Who Received SUTENT in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo^{*}

Rash	14	1	9	0
Hand-foot syndrome	14	4	10	3
Neurology				
Altered taste	21	0	12	0
Musculoskeletal				
Myalgia/limb pain	14	1	9	1
Metabolism/Nutrition				
Anorexia [†]	33	1	29	5
Asthenia	22	5	11	3
		1. 1.	N T 1	6

Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients.

* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

[†] Includes decreased appetite.

In the double-blind treatment phase of GIST Study 1, oral pain other than mucositis/stomatitis occurred in 12 patients (6%) on SUTENT versus 3 (3%) on placebo. Hair color changes occurred in 15 patients (7%) on SUTENT versus 4 (4%) on placebo. Alopecia was observed in 10 patients (5%) on SUTENT versus 2 (2%) on placebo.

Table 2 provides common (\geq 10%) treatment-emergent laboratory abnormalities.

	GIST			
	SUTENT	SUTENT (N=202)		(N=102)
Laboratory	All Grades*	Grade 3–	All Grades*	
Parameter	%	4 ^{*,†} %	%	4 ^{*,‡} %
Any		68 (34)		22 (22)
Gas trointes tinal				
AST/ALT	39	2	23	1
Lipase	25	10	17	7
Alkaline phosphatase	24	4	21	4
Amylase	17	5	12	3
Total bilirubin	16	1	8	0
Indirect bilirubin	10	0	4	0
Cardiac				
Decreased LVEF	11	1	3	0
Renal/Metabolic				
Creatinine	12	1	7	0
Potassium decreased	12	1	4	0
Sodium increased	10	0	4	1
Hematology				
Neutrophils	53	10	4	0
Lymphocytes	38	0	16	0
Platelets	38	5	4	0
Hemoglobin	26	3	22	2

Table 2. Laboratory Abnormalities Reported in Study 1 in ≥10% of GIST Patients Who Received SUTENT or Placebo in the Double-Blind Treatment Phase^{*}

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients.

- * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
- [†] Grade 4 laboratory abnormalities in patients on SUTENT included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%).
- [‡] Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%).

After an interim analysis, the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label SUTENT treatment *[see Clinical Studies (14.1)]*. For 241 patients randomized to the SUTENT arm, including 139 who received SUTENT in both the double-blind and open-label treatment phases, the median duration of SUTENT treatment was 6 cycles (mean: 8.5; range: 1–44). For the 255 patients who ultimately received open-label SUTENT treatment, median duration of study treatment was 6 cycles (mean: 7.8; range: 1–37) from the time of the unblinding. A total of 118 patients (46%) required dosing interruptions, and a total of 72 patients (28%) required dose reductions. The incidence of treatment-emergent adverse reactions resulting in permanent discontinuation was 20%. The most common Grade 3 or 4 treatment-related adverse reactions experienced by patients receiving SUTENT in the open-label treatment phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%).

Advanced Renal Cell Carcinoma (RCC)

The safety of SUTENT was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received SUTENT 50 mg daily on Schedule 4/2 (n=375) or IFN- α 9 million International Units (MIU) (n=360). The median duration of treatment was 11.1 months (range: 0.4–46.1) for SUTENT treatment and 4.1 months (range: 0.1–45.6) for IFN- α treatment. Dose interruptions occurred in 202 patients (54%) on SUTENT and 141 patients (39%) on IFN- α . Dose reductions occurred in 194 patients (52%) on SUTENT and 98 patients (27%) on IFN- α . Discontinuation rates due to adverse reactions were 20% for SUTENT and 24% for IFN- α . Most treatment-emergent adverse reactions in both study arms were Grade 1 or 2 in severity. Grade 3 or 4 treatment-emergent adverse reactions were reported in 77% versus 55% of patients on SUTENT versus IFN- α , respectively.

Table 3 compares the incidence of common ($\geq 10\%$) treatment-emergent adverse reactions for patients receiving SUTENT versus IFN- α .

	Treatment-Naïve RCC			
	SUTENT	Г (N=375)	IFN-α (N=360)
	All Grades	Grade 3–4 [†]	All Grades	Grade 3–4 [‡]
Adverse Reaction	%	%	%	%
Any Adverse	99	77	99	55
Reaction	55	//	55	55
Constitutional				
Fatigue	62	15	56	15
Asthenia	26	11	22	6
Fever	22	1	37	<1
Weight decreased	16	<1	17	1
Chills	14	1	31	0
Chest Pain	13	2	7	1
Influenza like illness	5	0	15	<1

Table 3. Adverse Reactions Reported in Study 3 in $\geq 10\%$ of Patients With RCC Who Received SUTENT or IFN- α^*

Gas trointes tinal				
Diarrhea	66	10	21	<1
Nausea	58	6	41	2
Mucositis/stomatitis	47	3	5	<1
Vomiting	39	5	17	1
Dyspepsia	34	2	4	0
Abdominal pain [§]	30	5	12	1
Constipation	23	1	14	<1
Dry mouth	13	0	7	<1 <1
GERD/reflux	15	U	,	~1
esophagitis	12	<1	1	0
Flatulence	14	0	2	0
Oral pain	14	<1	1	0
Glossodynia	14	0	1	0
Hemorrhoids	10	0	2	0
Cardiac	10		<u> </u>	<u> </u>
Hypertension	34	13	4	<1
Edema peripheral	24	2	4 5	1
Election fraction	24	2	5	1
decreased	16	3	5	2
Dermatology				
Rash	29	2	11	<1
	29	8	1	0
Hand-foot syndrome Skin	25	0	1	0
discoloration/yellow	25	<1	0	0
skin				
Dry skin	23	<1	7	0
Hair color changes	20	0	<1	0
Alopecia	14	0	9	0
Erythema	12	<1	1	0
Pruritus	12	<1	7	<1
Neurology				
Altered taste [¶]	47	<1	15	0
Headache	23	1	19	0
Dizziness	11	<1	14	1
Musculoskeletal				
Back pain	28	5	14	2
Arthralgia	30	3	19	1
Pain in extremity/limb	40	5	30	2
discomfort	40	5		۷
Endocrine				
Hypothyroidism	16	2	1	0
Respiratory				
Cough	27	1	14	<1
Dyspnea	26	6	20	4
Nasopharyngitis	14	0	2	0
Oropharyngeal pain	14	<1	2	0
Upper respiratory	11	~1	n	0

11	~1	۷	U
48	3	42	2
37	4 ^Þ	10	1
15	<1	10	0
11	0	14	1
	48	48 3 37 4 ^b	48 3 42 37 4^{p} 10 15 <1 10

Abbreviations: ARs=adverse reactions; IFN=interferon- α ; N=number of patients; RCC=renal cell carcinoma.

* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

[†] Grade 4 ARs in patients on SUTENT included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%) and rash (<1%).

[‡] Grade 4 ARs in patients on IFN-α included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%).

§ Includes flank pain.

¶ Includes ageusia, hypogeusia, and dysgeusia.

Includes decreased appetite.

^b Includes 1 patient with Grade 5 gastric hemorrhage.

ß Includes depressed mood.

Treatment-emergent Grade 3–4 laboratory abnormalities are presented in Table 4.

	Treatment-Naïve RCC			
	SUTENT	C (N=375)	IFN-α (N=360)	
Laboratory	All Grades*		All Grades*	Grade 3–
Parameter	%	4 ^{*,†} %	%	4 ^{*,‡} %
Gas trointes tinal				
AST	56	2	38	2
ALT	51	3	40	2
Lipase	56	18	46	8
Alkaline phosphatase	46	2	37	2
Amylase	35	6	32	3
Total bilirubin	20	1	2	0
Indirect bilirubin	13	1	1	0
Renal/Metabolic				
Creatinine	70	<1	51	<1
Creatine kinase	49	2	11	1
Uric acid	46	14	33	8
Calcium decreased	42	1	40	1
Phosphorus	31	6	24	6
Albumin	28	1	20	0
Glucose increased	23	6	15	6
Sodium decreased	20	8	15	4
Glucose decreased	17	0	12	<1
Potassium increased	16	3	17	4

Table 4. Laboratory Abnormalities Reported in Study 3 in $\geq 10\%$ of Treatment-Naïve RCC Patients Who Received SUTENT or IFN- α

Calcium increased	13	<1	10	1
Potassium decreased	13	1	2	<1
Sodium increased	13	0	10	0
Hematology				
Neutrophils	77	17	49	9
Hemoglobin	79	8	69	5
Platelets	68	9	24	1
Lymphocytes	68	18	68	26
Leukocytes	78	8	56	2

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; IFN=interferon- α ; N=number of patients; RCC=renal cell carcinoma.

* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

- [†] Grade 4 laboratory abnormalities in patients on SUTENT included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%).
- [‡] Grade 4 laboratory abnormalities in patients on IFN-α included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%).

Long-Term Safety in RCC

The long-term safety of SUTENT in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with SUTENT did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4.

Adjuvant Treatment of RCC

The safety of SUTENT was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received SUTENT 50 mg daily (n=306) on Schedule 4/2 or placebo (n=304). The median duration of treatment was 12.4 months (range: 0.13–14.9) for SUTENT and 12.4 months (range: 0.03–13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients on SUTENT and 6% on placebo. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions or delays occurred in 166 (54%) and 84 (28%) patients on SUTENT and placebo, respectively. One hundred forty patients (45.8%) out of 306 patients in the SUTENT arm and 15 patients (5%) out of 304 patients in the placebo arm had dose reductions.

Table 5 compares the incidence of common ($\geq 10\%$) treatment-emergent adverse reactions for patients receiving SUTENT versus placebo.

Table 5. Adverse Reactions Reported in S-TRAC in ≥10% of Patients With RCC Who Received SUTENT and More Commonly Than in Patients Given Placebo*

Adjuvant Treatment of RCC			
SUTENT (N=306)	Placebo (N=304)		

Adverse Reaction	All Grades %	Grade 3–4 %	All Grades %	Grade 3–4 %
Any Adverse				
Reaction	99	60	88	15
Constitutional				
Fatigue/Asthenia	57	8	34	2
Localized edema [†]	18	<1	<1	0
Pyrexia	12	<1	6	0
Gas trointes tinal				
Mucositis/Stomatitis [‡]	61	6	15	0
Diarrhea	57	4	22	<1
Nausea	34	2	15	0
Dyspepsia	27	1	7	0
Abdominal pain [§]	25	2	9	<1
Vomiting	19	2	7	0
Constipation	12	0	11	0
Cardiac				
Hypertension [¶]	39	8	14	1
Edema/Peripheral	10	<1	7	0
edema	10	<u></u>	/	0
Dermatology				
Hand-foot syndrome	50	16	10	<1
Hair color changes	22	0	2	0
Rash [#]	24	2	12	0
Skin				
discoloration/Yellow skin	18	0	1	0
Dry skin	14	0	6	0
Neurology				
Altered taste ^b	38	<1	6	0
Headache	19	<1	12	0
Musculoskeletal				
Pain in extremity	15	<1	7	0
Arthralgia	11	<1	10	0
Endocrine				
Hypothyroidism/TSH increased	24	<1	4	0
Metabolism/Nutrition				
Anorexia/Decreased appetite	19	<1	5	0
Hemorrhage/Bleeding				
Bleeding events, all sites ^ß	24	<1	5	<1

Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma.

* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
† Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema.

[‡] Includes mucosal inflammation, stomatitis apthous ulcer, mouth ulceration, tongue

ulceration, oropharyngeal pain and oral pain.

- § Includes abdominal pain, abdominal pain lower, and abdominal pain upper.
- Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis.
- [#] Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic.
- ^b Includes ageusia, hypogeusia, and dysgeusia.
- ß Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, hematuria.

Grade 4 adverse reactions in patients on SUTENT included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (< 1%), stomatitis (<1%), and pyrexia (< 1%). Grade 4 adverse reactions in patients on placebo included asthenia (<1%) and hypertension (<1%).

Grade 3–4 laboratory abnormalities that occurred in \geq 2% of patients receiving SUTENT include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%).

Advanced Pancreatic Neuroendocrine Tumors (pNET)

The safety of SUTENT was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received SUTENT 37.5 mg daily continuous dosing (n=83) or placebo (n=82). The median number of days on treatment was 139 days (range: 13–532 days) for patients on SUTENT and 113 days (range: 1–614 days) for patients on placebo. Nineteen patients (23%) on SUTENT and 4 patients (5%) on placebo were on study for >1 year. Dose interruptions occurred in 25 patients (30%) on SUTENT and 10 patients (12%) on placebo. Dose reductions occurred in 26 patients (31%) on SUTENT and 9 patients (11%) on placebo. Discontinuation rates due to adverse reactions were 22% for SUTENT and 17% for placebo.

Most treatment-emergent adverse reactions in both study arms were Grade 1 or 2 in severity. Grade 3 or 4 treatment-emergent adverse reactions were reported in 54% versus 50% of patients on SUTENT versus placebo, respectively. Table 6 compares the incidence of common ($\geq 10\%$) treatment-emergent adverse reactions for patients receiving SUTENT and reported more commonly in patients receiving SUTENT than in patients receiving placebo.

Table 6. Adverse Reactions Reported in the pNET Study 6 in $\geq 10\%$ ofPatients Who Received SUTENT and More Commonly Than in PatientsGiven Placebo*

	pNET			
	SUTEN	T (N=83)	Placebo) (N=82)
	All Grades	Grade 3–4 [†]	All Grades	Grade 3–4
Adverse Reaction	%	%	%	%
Any Adverse	99	54	95	50
Reaction	99	54	95	50
Constitutional				
Asthenia	34	5	27	4
Fatigue	33	5	27	9
Weight decreased	16	1	11	0
Gas trointes tinal				
Diarrhea	59	5	39	2
Stomatitis/oral	40	C	10	Λ

syndro mes [‡]	40	σ	10	U
Nausea	45	1	29	1
Abdominal pain [§]	39	5	34	10
Vomiting	34	0	31	2
Dyspepsia	15	0	6	0
Cardiac				
Hypertension	27	10	5	1
Dermatology				
Hair color changes	29	1	1	0
Hand-foot syndrome	23	6	2	0
Rash	18	0	5	0
Dry skin	15	0	11	0
Neurology				
Dysgeusia	21	0	5	0
Headache	18	0	13	1
Musculoskeletal				
Arthralgia	15	0	6	0
Psychiatric				
Insomnia	18	0	12	0
Hemorrhage/Bleeding				
Bleeding events [¶]	22	0	10	4
Epistaxis	21	1	5	0

Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors.

* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

- [†] Grade 4 adverse reactions in patients on SUTENT included fatigue (1%).
- [‡] Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth.
- § Includes abdominal discomfort, abdominal pain, and abdominal pain upper.
- Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia.

Table 7 provides common (\geq 10%) treatment-emergent laboratory abnormalities.

Table 7. Laboratory Abnormalities Reported in the pNET Study 6 in ${\geq}10\,\%$ of Patients Who Received SUTENT

	pNET						
	SUTENT			Placebo			
Laboratory Parameter	Ν	All Grades* %	Grade 3– 4 ^{*,†} %	Ν	All Grades* %	Grade 3– 4 ^{*,‡} %	
Gas trointes tinal							
AST increased	82	72	5	80	70	3	
ALT increased	82	61	4	80	55	3	
Alkaline phosphatase increased	82	63	10	80	70	11	
Total bilirubin increased	82	37	1	80	28	4	
Amylase increased	74	20	4	74	10	1	

Lipase increased	75	17	5	72	11	4
Renal/Metabolic						
Glucose increased	82	71	12	80	78	18
Albumin decreased	81	41	1	79	37	1
Phosphorus decreased	81	36	7	77	22	5
Calcium decreased	82	34	0	80	19	0
Sodium decreased	82	29	2	80	34	3
Creatinine increased	82	27	5	80	28	5
Glucose decreased	82	22	2	80	15	4
Potassium decreased	82	21	4	80	14	0
Magnesium decreased	52	19	0	39	10	0
Potassium increased	82	18	1	80	11	1
Hematology						
Neutrophils decreased	82	71	16	80	16	0
Hemoglobin decreased	82	65	0	80	55	1
Platelets decreased	82	60	5	80	15	0
Lymphocytes decreased	82	56	7	80	35	4

Abbreviations: ALT=alanine aminotransferase;

AST=aspartate aminotransferase; N=number of patients;

pNET=pancreatic neuroendocrine tumors.

* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

[†] Grade 4 laboratory abnormalities in patients on SUTENT included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%).

[‡] Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%).

Venous Thromboembolic Events

In patients treated with SUTENT (N=7527) for GIST, advanced RCC, adjuvant treatment of RCC and pNET, 3.5% of patients experienced a venous thromboembolic event; 2.2% Grade 3–4.

Reversible Posterior Leukoencephalopathy Syndrome

There have been reports (<1%), some fatal, of patients presenting with seizures and radiological evidence of reversible posterior leukoencephalopathy syndrome (RPLS). Patients with seizures and signs/symptoms consistent with RPLS, such as hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness, should be controlled with medical management including control of hypertension. Temporary suspension of SUTENT is recommended; following resolution, treatment may be resumed at the discretion of the treating healthcare provider.

Pancreatic Function

Pancreatitis was observed in 5 patients (1%) receiving SUTENT for treatment-naïve RCC compared to 1 patient (<1%) receiving IFN- α . In a trial of patients receiving adjuvant treatment for RCC, 1 patient (<1%) on SUTENT and none on placebo experienced pancreatitis. Pancreatitis was observed in 1 patient (1%) receiving SUTENT for pNET and 1 patient (1%) receiving placebo.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of SUTENT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

<u>Blood and lymphatic system disorders</u>: hemorrhage associated with thrombocytopenia¹. Suspension of SUTENT is recommended; following resolution, treatment may be resumed at the discretion of the treating healthcare provider.

Gastrointestinal disorders: esophagitis.

<u>Hepatobiliary disorders:</u> cholecystitis, particularly acalculous cholecystitis.

Immune system disorders: hypersensitivity reactions, including angioedema.

<u>Infections and infestations</u>: serious infection (with or without neutropenia)¹. The infections most commonly observed with SUTENT treatment include respiratory, urinary tract, skin infections, and sepsis/septic shock.

<u>Musculoskeletal and connective tissue disorders</u>: fistula formation, sometimes associated with tumor necrosis and/or regression¹; myopathy and/or rhabdomyolysis with or without acute renal failure¹. Patients with signs or symptoms of muscle toxicity should be managed as per standard medical practice.

<u>Renal and urinary disorders:</u> renal impairment and/or failure¹.

<u>Respiratory disorders:</u> pulmonary embolism¹.

<u>Skin and subcutaneous tissue disorders:</u> pyoderma gangrenosum, including positive dechallenges. <u>Vascular disorders:</u> arterial thromboembolic events¹. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction.

1 including some fatalities.

7 DRUG INTERACTIONS

7.1 CYP3A4 Inhibitors

Strong CYP3A4 inhibitors such as ketoconazole may **increase** sunitinib plasma concentrations. Selection of an alternate concomitant medication with no or minimal enzyme inhibition potential is recommended. Concurrent administration of SUTENT with the strong CYP3A4 inhibitor, ketoconazole, resulted in 49% and 51% increases in the combined (sunitinib + primary active metabolite) C_{max} and $AUC_{0-\infty}$ values, respectively, after a single dose of SUTENT in healthy volunteers. Coadministration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase sunitinib concentrations. Grapefruit may also increase plasma concentrations of sunitinib. A dose reduction for SUTENT should be considered when it must be coadministered with strong CYP3A4 inhibitors [*see Dosage and Administration (2.4)*].

7.2 CYP3A4 Inducers

CYP3A4 inducers such as rifampin may **decrease** sunitinib plasma concentrations. Selection of an alternate concomitant medication with no or minimal enzyme induction potential is recommended. Concurrent administration of SUTENT with the strong CYP3A4 inducer, rifampin, resulted in a 23% and 46% reduction in the combined (sunitinib + primary active metabolite) C_{max} and $AUC_{0-\infty}$ values, respectively, after a single dose of SUTENT in healthy volunteers. Coadministration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort) may decrease sunitinib concentrations. St. John's Wort may decrease sunitinib plasma concentrations unpredictably. Patients receiving SUTENT should not take St. John's Wort concomitantly. A dose increase for SUTENT should be considered when it must be coadministered with CYP3A4 inducers [*see Dosage and Administration (2.4)*].

7.3 In Vitro Studies of CYP Inhibition and Induction

In vitro studies indicated that sunitinib does not induce or inhibit major CYP enzymes. The in vitro

studies in human liver microsomes and hepatocytes of the activity of CYP isoforms CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 indicated that sunitinib and its primary active metabolite are unlikely to have any clinically relevant drug-drug interactions with drugs that may be metabolized by these enzymes.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

<u>Risk Summary</u>

Based on animal reproduction studies and its mechanism of action, SUTENT can cause fetal harm when administered to a pregnant woman *[see Clinical Pharmacology (12.1)]*. There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the AUC in patients administered the recommended daily doses (RDD), respectively *(see Data)*. Advise pregnant women or females of reproductive potential of the potential hazard to a fetus.

The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the estimated background risk in the United States (U.S.) general population of major birth defects is 2%–4% and of miscarriage is 15%–20% of clinically recognized pregnancies.

<u>Data</u>

Animal Data

In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the AUC in patients administered the RDD of 50 mg/day).

In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the systemic exposure [combined AUC of sunitinib + primary active metabolite] in patients administered the RDD). No adverse fetal effects were observed in rats at doses \leq 3 mg/kg/day (approximately 2 times the AUC in patients administered the RDD). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the AUC in patients administered the RDD), and craniofacial malformations (cleft lip and cleft palate) were observed at \geq 1 mg/kg/day (approximately 0.3 times the AUC in patients administered the RDD of 50 mg/day).

Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses ≥ 1 mg/kg/day (approximately 0.5 times the AUC in patients administered the RDD). At 3 mg/kg/day (approximately 2 times the AUC in patients administered the RDD), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses ≤ 1 mg/kg/day.

8.2 Lactation

There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (*see Data*). Because of the potential for serious adverse reactions in breastfed infants from SUTENT, advise a lactating woman not to breastfeed during treatment with SUTENT and for at least 4 weeks after the last dose.

Animal Data

In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma.

8.3 Females and Males of Reproductive Potential

Based on animal reproduction studies and its mechanism of action, SUTENT can cause fetal harm when administered to a pregnant woman [see Pregnancy (8.1) and Clinical Pharmacology (12.1)].

Pregnancy Testing

Females of reproductive potential should have a pregnancy test before treatment with SUTENT is started.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with SUTENT and for at least 4 weeks after the last dose.

Males

Based on findings in animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment with SUTENT and for 7 weeks after the last dose.

Infertility

Based on findings in animals, male and female fertility may be compromised by treatment with SUTENT [see Nonclinical Toxicology (13.1)].

8.4 Pediatric Use

The safety and efficacy of SUTENT in pediatric patients have not been established.

Physeal dysplasia was observed in cynomolgus monkeys with open growth plates treated for \geq 3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) with sunitinib at doses that were >0.4 times the RDD based on systemic exposure (AUC). In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \geq 5 mg/kg (approximately 10 times the RDD based on AUC). Additionally, caries of the teeth were observed in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and were reversible upon cessation of treatment; however, findings in the teeth were not. A no-effect level was not observed in monkeys treated continuously for 3 months, but was 1.5 mg/kg/day when treated intermittently for 8 cycles. In rats the no-effect level in bones was \leq 2 mg/kg/day.

8.5 Geriatric Use

Of 825 patients with GIST or metastatic RCC who received SUTENT on clinical studies, 277 (34%) were 65 and over. In the pNET study, 22 patients (27%) who received SUTENT were 65 and over. No overall differences in safety or effectiveness were observed between younger and older patients. Among the 158 patients at least age 65 receiving adjuvant SUTENT/placebo for RCC, the hazard ratio for disease-free survival was 0.59 (95% CI: 0.36, 0.95). Among patients 65 years and older receiving adjuvant SUTENT/placebo for RCC, 50 patients (16%) in the SUTENT arm experienced a Grade 3–4 adverse reaction, compared to 15 patients (5%) in the placebo arm.

8.6 Hepatic Impairment

No dose adjustment to the starting dose is required when administering SUTENT to patients with Child-

Pugh Class A or B hepatic impairment. Sunitinib and its primary metabolite are primarily metabolized by the liver. Systemic exposures after a single dose of SUTENT were similar in patients with mild or moderate (Child-Pugh Class A and B) hepatic impairment compared to patients with normal hepatic function. SUTENT was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. Studies in cancer patients have excluded patients with ALT or AST >2.5 × ULN or, if due to liver metastases, >5.0 × ULN.

8.7 Renal Impairment

No adjustment to the starting dose is required when administering SUTENT to patients with mild (CLcr 50–80 mL/min), moderate (CLcr 30–<50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis. In patients with end-stage renal disease (ESRD) on hemodialysis, no adjustment to the starting dose is required. However, compared to patients with normal renal function, the sunitinib exposure is 47% lower in patients with ESRD on hemodialysis. Therefore, the subsequent doses may be increased gradually up to 2-fold based on safety and tolerability.


10 OVERDOSAGE

Treatment of overdose with SUTENT should consist of general supportive measures. There is no specific antidote for overdosage with SUTENT. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of SUTENT, or without adverse reactions. A case of intentional overdose involving the ingestion of 1500 mg of SUTENT in an attempted suicide was reported without adverse reaction. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3000 mg/m²) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations.

11 DESCRIPTION

SUTENT, an oral multi-kinase inhibitor, is the malate salt of sunitinib. Sunitinib malate is described chemically as Butanedioic acid, hydroxy-, (2S)-, compound with *N*-[2-(diethylamino)ethyl]-5-[(*Z*)-(5-fluoro-1,2-dihydro-2-oxo-3*H*-indol-3-ylidine)methyl]-2,4-dimethyl-1*H*-pyrrole-3-carboxamide (1:1). The molecular formula is $C_{22}H_{27}FN_4O_2 \cdot C_4H_6O_5$ and the molecular weight is 532.6 Daltons.

The chemical structure of sunitinib malate is:



Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2.

SUTENT (sunitinib malate) capsules are supplied as printed hard shell capsules containing sunitinib malate equivalent to 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib together with mannitol, croscarmellose sodium, povidone (K-25) and magnesium stearate as inactive ingredients.

The orange gelatin capsule shells contain titanium dioxide and red iron oxide. The caramel gelatin capsule shells contain titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide. The yellow gelatin capsule shells contain titanium dioxide and yellow iron oxide. The white printing ink contains shellac, propylene glycol, sodium hydroxide, povidone, and titanium dioxide. The black printing ink contains shellac, propylene glycol, potassium hydroxide, and black iron oxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR α and PDGFR β), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.

Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRβ, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRβ- and VEGFR2-dependent tumor angiogenesis in vivo.

12.3 Pharmacokinetics

The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in 135 healthy volunteers and in 266 patients with solid tumors.

Maximum plasma concentrations (C_{max}) of sunitinib are generally observed between 6 and 12 hours (time to maximum plasma concentration [T_{max}]) following oral administration. Food has no effect on the bioavailability of sunitinib. SUTENT may be taken with or without food.

Binding of sunitinib and its primary active metabolite to human plasma protein in vitro was 95% and 90%, respectively, with no concentration dependence in the range of 100–4000 ng/mL. The apparent volume of distribution (Vd/F) for sunitinib was 2230 L. In the dosing range of 25–100 mg, the AUC and C_{max} increase proportionately with dose.

Sunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to produce its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. Elimination is primarily via feces. In a human mass balance study of [¹⁴C]sunitinib, 61% of the dose was eliminated in feces, with renal elimination accounting for 16% of the administered dose. Sunitinib and its primary active metabolite were the major drug-related compounds identified in plasma, urine, and feces, representing 91.5%, 86.4%, and 73.8% of radioactivity in pooled samples, respectively. Minor metabolites were identified in urine and feces but generally not found in plasma. Total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient

variability of 40%.

Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 62.9–101 ng/mL. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles in the dosing regimens tested.

The pharmacokinetics were similar in healthy volunteers and in the solid tumor patient populations tested, including patients with GIST and RCC.

Pharmacokinetics in Special Populations

Population pharmacokinetic analyses of demographic data indicate that there are no clinically relevant effects of age, body weight, creatinine clearance, race, gender, or Eastern Cooperative Oncology Group (ECOG) score on the pharmacokinetics of SUTENT or the primary active metabolite.

Pediatric Use: The pharmacokinetics of SUTENT have not been evaluated in pediatric patients.

Renal Insufficiency: Sunitinib systemic exposure after a single dose of SUTENT was similar in patients with severe renal impairment ($CL_{cr} < 30 \text{ mL/min}$) compared to patients with normal renal function ($CL_{cr} > 80 \text{ mL/min}$). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with ESRD on hemodialysis compared to patients with normal renal function.

Hepatic Insufficiency: Systemic exposures after a single dose of SUTENT were similar in patients with mild exocrine (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment compared to patients with normal hepatic function.

12.4 Cardiac Electrophysiology

SUTENT can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes *[see Warnings and Precautions (5.3)]*.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at doses $\geq 25 \text{ mg/kg/day}$ following daily dose administration of sunitinib in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day (approximately 0.9 times the AUC in patients given the RDD of 50 mg/day). At the high dose of 3 mg/kg/day (approximately 8 times the AUC in patients at the RDD of 50 mg/day), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland.

Sunitinib did not cause genetic damage when tested in in vitro assays (bacterial mutation [Ames test], human lymphocyte chromosome aberration) and an in vivo rat bone marrow micronucleus test.

In a female fertility and early embryonic development study, female rats were administered oral sunitinib

(0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the AUC in patients administered the RDD of 50 mg/day). No adverse effects on fertility were observed at doses \leq 1.5 mg/kg/day (approximately 1 time the clinical AUC at the RDD of 50 mg/day). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the AUC in patients administered the RDD), while uterine changes (endometrial atrophy) were noted at \geq 2 mg/kg/day (approximately 0.4 times the AUC in patients administered the RDD). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the AUC in patients administered the RDD) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14 day respite).

In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \leq 10 mg/kg/day approximately \geq 26 times the AUC in patients administered the RDD).

14 CLINICAL STUDIES

14.1 Gas trointes tinal Stromal Tumor

<u>Study 1</u>

Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of SUTENT in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving SUTENT plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg SUTENT or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label SUTENT and patients randomized to SUTENT were permitted to continue treatment per investigator judgment.

At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the SUTENT arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the SUTENT and placebo groups with regard to age (69% versus 72% <65 years for SUTENT versus placebo, respectively), gender (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced.

The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for SUTENT over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 8 and the Kaplan-Meier curve for TTP is shown in Figure 1.

Table 8. GIST Efficacy Results From Study 1 (Double-Blind Treatment
Phase)




Efficacy Parameter	(11-207)	(11-105)	test)	(32% (1)
Time-to-tumor progression [*] [median, weeks (95% CI)]	27.3 (16.0, 32.1)	6.4 (4.4, 10.0)	<0.0001 [†]	0.33 (0.23, 0.47)
Progression-free survival [‡] [median, weeks (95% CI)]	24.1 (11.1, 28.3)	6.0 (4.4, 9.9)	<0.0001	0.33 (0.24, 0.47)
Objective response rate (PR) [%, (95% CI)]	6.8 (3.7, 11.1)	0	0.006 [§]	

Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response.

- * Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation.
- [†] A comparison is considered statistically significant if the p-value is <0.00417 (O'Brien Fleming stopping boundary).
- [‡] Time from randomization to progression or death due to any cause.
- § Pearson chi-square test.





Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression.

The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the SUTENT arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis, the study was unblinded, and patients on the placebo arm were offered open-label SUTENT treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive SUTENT in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the SUTENT arm and 64.9 weeks for the placebo arm [hazard ratio (HR)=0.876, 95% confidence interval (CI) (0.679, 1.129)].

Study 2

Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the

recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of SUTENT on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%).

14.2 Renal Cell Carcinoma

Treatment-Naïve RCC

Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent SUTENT with IFN- α was conducted in patients with treatment-naïve RCC. The objective was to compare PFS in patients receiving SUTENT versus patients receiving IFN- α . Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg SUTENT once daily on Schedule 4/2 or to receive IFN- α administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study.

The ITT population included 750 patients, 375 randomized to SUTENT and 375 randomized to IFN- α . Demographics were comparable between the SUTENT and IFN- α groups with regard to age (59% versus 67% <65 years for SUTENT versus IFN- α , respectively), gender (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively).

There was a statistically significant advantage for SUTENT over IFN- α in the endpoint of PFS (see Table 9 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (>1.5 ULN versus \leq 1.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored SUTENT over IFN- α . The ORR was higher in the SUTENT arm (see Table 9).

Efficacy Parameter	SUTENT (N=375)	IFN-α (N=375)	p-value (log-rank test)	HR (95% CI)
Progression-free survival*	47.3 (42.6,	22.0	<0.000001 ⁺	0.415 (0.320,
[median, weeks (95% CI)]	(42.0, 50.7)	(16.4, 24.0)	<0.000001	(0.520, 0.539)
Objective response rate [*]	27.5	5.3	<0.001 [‡]	NA
[%, (95% CI)]	(23.0, 32.3)	(3.3, 8.1)	0.001	

Table 9. Treatment-Naïve RCC Efficacy Results (Interim Analysis)


Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; INF- α =interferon-alfa; NA=not applicable; RCC=renal cell carcinoma.

* Assessed by blinded core radiology laboratory; 90 patients' scans had not been read at time of analysis.

[†] A comparison is considered statistically significant if the p-value is <0.0042 (O'Brien Fleming stopping boundary).

[‡] Pearson chi-square test.

Figure 2. Kaplan-Meier Curve of PFS in Treatment-Naïve RCC Study 3 (Intent-to-Treat Population)



Abbreviations: CI=confidence interval; INF- α =interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma.

At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the SUTENT arm and 94.9 weeks for the IFN- α arm (HR=0.821; 95% CI: 0.673, 1.001). The median OS for the IFN- α arm includes 25 patients who discontinued IFN- α treatment because of disease progression and crossed over to treatment with SUTENT as well as 121 patients (32%) on the IFN- α arm who received post-study cancer treatment with SUTENT.

Cytokine-Refractory RCC

The use of single-agent SUTENT in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (IFN- α , interleukin-2, or IFN- α plus interleukin-2; patients who were treated with IFN- α alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated.

One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg SUTENT on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, gender, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86%–94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status <2 at the screening visit.

The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81%

of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies.

The ORR and DR data from Studies 4 and 5 are provided in Table 10. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (>90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff.

Efficacy Parameter	Study 4 (N=106)	Study 5 (N=63)
Objective response rate	34.0^{*}	36.5 [†]
[%, (95% CI)]	(25.0, 43.8)	(24.7, 49.6)
Duration of response	NR^{\ddagger}	54^{\dagger}
[median, weeks (95% CI)]	(42.0, [‡])	(34.3, 70.1)

Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma.

* Assessed by blinded core radiology laboratory.

[†] Assessed by investigators.

[‡] Data not mature enough to determine upper confidence limit.

<u>Adjuvant Treatment of RCC</u>

In the adjuvant treatment setting, SUTENT was investigated in S-TRAC (NCT#00375674), a multicenter, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \geq T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg SUTENT once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent.

Demographics were generally comparable between the SUTENT and placebo arms with regard to age (median age 58 years), gender (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% SUTENT and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on SUTENT had a performance status of 2.

The major efficacy outcome measure was disease-free survival (DFS) in patients receiving SUTENT versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with SUTENT compared to placebo (Table 11 and Figure 3). Prespecified subgroup analyses are presented in Table 12. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths.

Table 11. Disease-free Survival Results as Assessed by BICR inAdjuvant RCC (Intent to Treat Population)

SUTENT	Placebo	n valua*	HR [*] (95%
N = 309	N = 306	p-value	CI)

Median DFS [years (95% CI)]	6.8 (5.8, NR)	5.6 (3.8, 6.6)	0.03	0.76 (0.59, 0.98)
DFS Events	113 (36.6%)	144 (47.1%)		
5 Year DFS Rate	59.3%	51.3%		

Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma.

* P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group

Table 12. Disease-free Survival by Baseline Disease Characteristics

	Number of Events/ Total n/N		Media [years (9	HR* (95% CI)	
	SUTENT	Placebo	SUTENT	Placebo	
T3 Intermediate [†]	35/115	46/112	NR (5.2, NR)	6.4 (4.7, NR)	0.82 (0.53, 1.28)
T3 High [‡]	63/165	79/166	6.8 (5.0, NR)	5.3 (2.9, NR)	0.77 (0.55, 1.07)
T4/Node Positive [§]	15/29	19/28	3.5 (1.2, NR)	1.7 (0.4, 3.0)	0.62 (0.31, 1.23)

Abbreviations: CI=confidence interval; DFS=disease-free survival;


HR=hazard ratio; N=number of patients; n=number of events; NR=not reached

* HR based on a Cox proportional hazards model

⁺ T3 Intermediate: T3, N0 or NX, M0, any Fuhrman's grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman's grade 1, ECOG PS ≥ 1

- [‡] T3 High: T3, N0 or NX, M0, Fuhrman's grade \geq 2, ECOG PS \geq 1
- § T4/Node Positive: T4, N0 or NX, M0, any Fuhrman's grade, any ECOG PS OR Any T, N1–2, M0, any Fuhrman's grade, any ECOG PS

Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population)



Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients.

14.3 Pancreatic Neuroendocrine Tumors

Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebocontrolled study of single-agent SUTENT conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg SUTENT (N=86) or placebo (N=85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving SUTENT versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study.

Demographics were comparable between the SUTENT and placebo groups. Additionally, 49% of SUTENT patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of SUTENT patients received prior systemic therapy compared with 72% of placebo patients and 35% of SUTENT patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to SUTENT in a separate extension study.

As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for SUTENT over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring SUTENT was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the SUTENT arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring SUTENT over placebo was observed. Efficacy results are summarized in Table 13 and the Kaplan-Meier curve for PFS is in Figure 4.

	SUTENT	Placebo	p-value	HR
Efficacy Parameter	(N=86)	(N=85)	p-value	(95% CI)


Progression-free survival [median, months (95% CI)]	10.2 (7.4, 16.9)	5.4 (3.4, 6.0)	0.000146^{*}	0.427 (0.271, 0.673)
Objective response rate [%, (95% CI)]	9.3 (3.2, 15.4)	0	0.0066^{+}	NA

Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors.

* 2-sided unstratified log-rank test.

[†] Fisher's Exact test.

Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6



Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors.

16 HOW SUPPLIED/STORAGE AND HANDLING

12.5 mg capsules

Hard gelatin capsule with orange cap and orange body, printed with white ink "Pfizer" on the cap, "STN 12.5 mg" on the body; available in: Bottles of 28 capsules: NDC 0069-0550-38

25 mg capsules

Hard gelatin capsule with caramel cap and orange body, printed with white ink "Pfizer" on the cap, "STN 25 mg" on the body; available in: Bottles of 28 capsules: NDC 0069-0770-38

37.5 mg capsules

Hard gelatin capsule with yellow cap and yellow body, printed with black ink "Pfizer" on the cap, "STN 37.5 mg" on the body; available in: Bottles of 28 capsules: NDC 0069-0830-38

50 mg capsules

Hard gelatin capsule with caramel cap and caramel body, printed with white ink "Pfizer" on the cap, "STN 50 mg" on the body; available in: Bottles of 28 capsules: NDC 0069-0980-38

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see United States Pharmacopeia (USP) Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

<u>Hepatotoxicity</u>

Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions (5.1)].

Cardiovascular Events

Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see *Warnings and Precautions* (5.2)].

QT Prolongation and Torsade de Pointes

Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [see Warnings and Precautions (5.3)].

Hypertension

Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions (5.4)].

Hemorrhagic Events

Advise patients that SUTENT can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding *[see Warnings and Precautions (5.5)]*.

Gastrointestinal Disorders

Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during SUTENT treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking SUTENT [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)].

Dermatologic Effects and Toxicities

Advise patients that depigmentation of the hair or skin may occur during treatment with SUTENT due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur *[see Warnings and Precautions (5.9) and Adverse Reactions (6.1)]*.

Thyroid Dysfunction

Advise patients that SUTENT can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur *[see Warnings and Precautions (5.10)]*.

<u>Hypoglycemia</u>

Advise patients that SUTENT can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions (5.11)].

Osteonecrosis of the Jaw

Advise patients to consider preventive dentistry prior to treatment with SUTENT. Inform patients being treated with SUTENT, particularly who are receiving bisphosphonates, to avoid invasive dental procedures if possible [see Warnings and Precautions (5.12)].

If possible, avoid invasive dental procedures while on SUTENT treatment, particularly in patients receiving intravenous bisphosphonate therapy.

Concomitant Medications

Advise patients to inform their healthcare providers of all concomitant medications, including over-thecounter medications and dietary supplements *[see Drug Interactions (7)]*.

Embryo-Fetal Toxicity

Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy [*see Use in Specific Populations* (8.1)].

Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of SUTENT [see Warnings and Precautions (5.14) and Use in Specific Populations (8.1, 8.3)].

Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of SUTENT [see Warnings and Precautions (5.14) and Use in Specific Populations (8.1, 8.3)].

<u>Lactation</u>

Advise lactating women not to breastfeed during treatment with SUTENT and for at least 4 weeks after the last dose [see Use in Specific Populations (8.2)].

<u>Infertility</u>

Advise patients that male and female fertility may be compromised by treatment with SUTENT [see Use in Specific Populations (8.3) and Nonclinical Toxicology (13.1)].

Missed Dose

Advise patients that miss a dose of SUTENT by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of SUTENT by more than 12 hours to take the next scheduled dose at its regular time.

This product's label may have been updated. For full prescribing information, please visit www.pfizer.com.

Distributed by



LAB-0317-22.0

Capsules

What is the most important information I should know about SUTENT? SUTENT can cause serious side effects including:

- Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with SUTENT:
 - itching
 - yellow eyes or skin
 - dark urine
 - pain or discomfort in the right upper stomach area

Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with SUTENT. Your healthcare provider may tell you to temporarily or permanently stop taking SUTENT if you develop liver problems.

See "What are the possible side effects of SUTENT?" for more information about side effects.

What is SUTENT?

SUTENT is a prescription medicine used to treat:

- a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when:
 - $\circ~$ you have taken the medicine imatinib mesylate (Gleevec $^{\textcircled{R}}$) and it did not stop the cancer from growing, or
 - you cannot take imatinib mesylate (Gleevec[®]).
- advanced kidney cancer (advanced renal cell carcinoma or RCC).
- adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery.
- a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery.

It is not known if SUTENT is safe and effective in children.

Before taking SUTENT tell your healthcare provider about all of your medical conditions, including if you:

- have any heart problems
- have high blood pressure
- have thyroid problems
- have a history of low blood sugar or diabetes
- have kidney function problems (other than cancer)
- have liver problems
- have any bleeding problem
- plan to have any surgery or dental procedures
- have seizures
- have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth
- are pregnant or plan to become pregnant. SUTENT can harm your unborn baby. **Females** who are able to become pregnant:
 - Your healthcare provider should do a pregnancy test before you start treatment with SUTENT.
 - You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of SUTENT.
 - Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with SUTENT.

Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of SUTENT.

SUTENT may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you.

• are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with SUTENT and for at least 4 weeks (1 month) after the last dose.

Tell all of your healthcare providers and dentists that you are taking SUTENT. They should talk to the healthcare provider who prescribed SUTENT for you, before you have **any** surgery, or medical or dental procedure.

Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using SUTENT with certain other medicines can cause serious side effects.

You may have an increased risk of severe jaw bone problems (osteonecrosis) if you take SUTENT and a bisphosphonate medicine. **Especially tell** your healthcare provider if you are taking or have taken an osteoporosis medicine.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take SUTENT?

- Take SUTENT exactly the way your healthcare provider tells you.
- Take SUTENT 1 time each day with or without food.
- If you take SUTENT for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to.
- If you take SUTENT for pNET, take it 1 time each day until your healthcare provider tells you to stop.
- Do not drink grapefruit juice or eat grapefruit during your treatment with SUTENT. They may cause you to have too much SUTENT in your body.
- Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects.
- If you miss a dose of Sutent by less than 12 hours, take the missed dose right away. If you miss a dose of SUTENT by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose.
- Call your healthcare provider right away, if you take too much SUTENT.

What are possible side effects of SUTENT?

SUTENT may cause serious side effects, including:

- See "What is the most important information I should know about SUTENT?"
- **Heart problems.** Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with SUTENT if you have signs and symptoms of heart failure.
- Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with SUTENT. Tell your healthcare provider immediately if you feel dizzy, faint, or have abnormal heartbeats during your treatment with SUTENT
 - you feel faint or lightheaded, or you pass out
 feel your
 - feel your heart beat is irregular or fast

- dizziness
- **High blood pressure.** High blood pressure is common with SUTENT, and may sometimes be severe. Follow your healthcare provider's instructions about having your blood pressure checked

regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure:

- severe headache dizziness
- lightheadedness change in vision

Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with SUTENT until your high blood pressure is controlled.

- **Bleeding problems**. Bleeding is common with SUTENT, but SUTENT can also cause severe bleeding problems that can lead to death. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with SUTENT, including:
 - painful, swollen stomach (abdomen)
- bloody urine

- vomiting blood
- black, sticky stools

headache or change in your mental statuscoughing up blood

- Your healthcare provider:
- can tell you about other symptoms to watch for
- may do blood tests if needed and monitor you for bleeding
- Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with SUTENT.
- **Tumor lysis syndrome (TLS).** TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.
- Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS). TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking SUTENT. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body's organs such as the brain and kidneys, and can sometimes lead to death. Your healthcare provider may tell you to stop taking SUTENT if you develop TMA.
- **Protein in your urine.** Some people who have taken SUTENT have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. If there is too much protein in your urine, your healthcare provider may tell you to stop taking SUTENT.
- **Serious skin and mouth reactions.** Treatment with SUTENT has caused severe skin reactions that can lead to death, including:
 - severe rash with blisters or peeling of the skin.
 - painful sores or ulcers on the skin, lips or inside the mouth.
 - tissue damage (necrotizing fasciitis).

If you have any signs or symptoms of severe skin reactions, stop taking SUTENT and call your healthcare provider or get medical help right away.

- **Thyroid problems.** Your healthcare provider may do tests to check your thyroid function during SUTENT treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with SUTENT:
 - tiredness that gets worse and does not go away
 - fast heat rate

• loss of appetite

• weight gain or weight loss

- problems with heat
- feeling nervous or agitated, tremors
- sweating
- nausea or vomiting

- feeling depressed
- irregular menstrual periods or no menstrual periods
- headache
- hair loss

- diarrhea
- Low blood sugar (hypoglycemia). Low blood sugar can happen with SUTENT, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with SUTENT may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with SUTENT and may need to adjust the dose of your antidiabetic medicines. Signs and symptoms of low blood sugar may include:
 - headache
 - drowsiness
 - weakness
 - dizziness
 - confusion

- irritability
- hunger
- fast heart beat
- sweating
- feeling jittery

Call your healthcare provider right away if you have any signs or symptoms of severe low blood sugar during your treatment with SUTENT.

- Jaw-bone problems (osteonecrosis). Severe jaw bone problems have happened in some people who take SUTENT. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking SUTENT. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with SUTENT, especially if you are receiving a bisphosphonate medicine into a vein (intravenous).
- **Wound healing problems**. Wounds may not heal properly during SUTENT treatment. Tell your healthcare provider if you have or plan to have any surgery before starting or during treatment with SUTENT.
 - Your healthcare provider may tell you to temporarily stop taking SUTENT if you are planning to have certain types of surgery.
 - Your healthcare provider should tell you when you may start taking SUTENT again after surgery.

Common side effects of SUTENT include:

- tiredness
- weakness
- diarrhea

- vomiting
- stomach-area (abdominal) pain
- pain, swelling or sores inside of your • mouth
- nausea
- loss of appetite • indigestion

- blisters or rash on the palms of your hands and soles of vour feet
- high blood pressure
- taste changes
- low platelet counts

The medicine in SUTENT is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. SUTENT may also cause other skin problems including: dryness, thickness or cracking of the skin.

These are not all of the possible side effects of SUTENT. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How do I store SUTENT?

• Store SUTENT at room temperature, between 68°F to 77°F (20°C to 25°C).

Keep SUTENT and all medicines out of the reach of children.

General information about the safe and effective use of SUTENT.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SUTENT for a condition for which it was not prescribed. Do not give SUTENT to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your healthcare provider or pharmacist for information about SUTENT that is written for health professionals.

What are the ingredients in SUTENT?

Active ingredient: sunitinib malate

Inactive ingredients: mannitol, croscarmellose sodium, povidone (K-25), and magnesium stearate. **Orange gelatin capsule shells:** titanium dioxide, and red iron oxide.

Caramel gelatin capsule shells: titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide.

Yellow gelatin capsule shells: titanium dioxide and yellow iron oxide.

White printing ink: shellac, propylene glycol, sodium hydroxide, povidone, and titanium dioxide.

Black printing ink: shellac, propylene glycol, potassium hydroxide and black iron oxide.

Distributed by



Pfizer Labs

Division of Pfizer Inc, NY, NY 10017

Gleevec[®] is a registered trademark of Novartis Pharmaceuticals Corporation. LAB-0361-10.0

For more information go to <u>www.SUTENT.com</u> or call 1-877-5-SUTENT.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Revised: November 2017

PRINCIPAL DISPLAY PANEL - 12.5 mg Capsule Bottle Label

ALWAYS DISPENSE WITH MEDICATION GUIDE

NDC 0069-0550-38

Pfizer

Sutent[®] (sunitinib malate)

12.5 mg*

Capsules

28 Capsules Rx only



PRINCIPAL DISPLAY PANEL - 25 mg Capsule Bottle Label *ALWAYS DISPENSE WITH MEDICATION GUIDE*

NDC 0069-0770-38


Pfizer

Sutent[®] (sunitinib malate)

25 mg*

Capsules

28 Capsules Rx only



PRINCIPAL DISPLAY PANEL - 50 mg Capsule Bottle Label

ALWAYS DISPENSE WITH MEDICATION GUIDE

NDC 0069-0980-38


Pfizer

Sutent[®] (sunitinib malate)

50 mg*

Capsules

28 Capsules Rx only



PRINCIPAL DISPLAY PANEL - 37.5 mg Capsule Bottle Label ALWAYS DISPENSE WITH MEDICATION GUIDE

NDC 0069-0830-38


Pfizer

Sutent[®] (sunitinib malate)

37.5 mg*

Capsules

28 Capsules Rx only



SUTENT					
sunitinib malate capsule					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code	(Source)	NDC:00	69-0550
Route of Administration	ORAL				
Active Ingredient/Active Moi	o tv				
-	gredient Name		Basis of Str	ength	Strength
SUNITINIB MALATE (UNII: LVX8N1U			SUNITINIB	0	12.5 mg
Inactive Ingredients					
mactive ingretients	In gradiant Nama			64	wowath
MANINETOL (UNIT 2014/ 521 20 A)	Ingredient Name			51	rength
MANNITOL (UNII: 30WL53L36A) CROSCARMELLOSE SODIUM (UNII:					
POVIDONE K25 (UNII: K0KQV10C35)					
MAGNESIUM STEARATE (UNII: 7009					
CHLATIN UNSPECIFIED (UNU 2686)	ON327I)				
GELATIN, UNSPECIFIED (UNII: 2G86					
TITANIUM DIO XIDE (UNII: 15FIX9 V2J	P)				
TITANIUM DIO XIDE (UNII: 15FIX9 V2J FERRIC O XIDE RED (UNII: 1K09F3G6	P)				
TITANIUM DIO XIDE (UNII: 15FIX9 V2J FERRIC O XIDE RED (UNII: 1K09F3G6 SHELLAC (UNII: 46N107B710)	75)				
TITANIUM DIOXIDE (UNII: 15FIX9 V2J FERRIC OXIDE RED (UNII: 1K09F3G6 SHELLAC (UNII: 46N107B710) PROPYLENE GLYCOL (UNII: 6DC9Q	16 7 V3)				
TITANIUM DIO XIDE (UNII: 15FIX9 V2J FERRIC O XIDE RED (UNII: 1K09F3G6 SHELLAC (UNII: 46N107B710)	IP) 75) 167V3) C32I)				

Product Character	vistics					
	ORANGE	Score		no score		
Color	CAPSULE Size 14mm					
Shape	CAPSULE					
Flavor	Imprint Code Pfizer;STN;12;5;m			mg		
Contains						
Packaging						
# Item Code		Package Description	Marke	ting Start Dat	e Marketi	ng End Date
1 NDC:0069-0550-38	28 in 1 BOTTL	E; Type 0: Not a Combination Product	0 1/26/2	006		
Marketing Info	rmation					
Marketing Category		on Number or Monograph Citation	n Mark	eting Start Dat	e Marketi	ng End Date
NDA	NDA021938		01/26/2	-		8 - Mu Duit
			0 1/20/2			
SUTENT						
	1					
sunitinib malate capsu	le					
Product Informati	on					
Product Type		HUMAN PRESCRIPTION DRUG	Ite m C	ode (Source)	NDC:0	069-0770
	on		Ite m C	ode (Source)	NDC:0	069-0770
Product Type Route of Administrati	on	HUMAN PRESCRIPTION DRUG	Item C	ode (Source)	NDC:0	069-0770
	on		Ite m C	ode (Source)	NDC:0	069-0770
Route of Administrati		ORAL	Item C	ode (Source)	NDC:0	069-0770
	Active Moi	ORAL ety	Ite m C			
Route of Administrati Active Ingredient/	Active Moi	ORAL ety gredient Name		Basis of	NDC:0	Strength
Route of Administrati Active Ingredient/	Active Moi	ORAL ety				
Route of Administrati Active Ingredient/	Active Moi	ORAL ety gredient Name		Basis of		Strength
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U	Active Moi Ing INII: LVX8N1U	ORAL ety gredient Name		Basis of		Strength
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U	Active Moi Ing INII: LVX8N1U	ORAL ety gredient Name		Basis of		Strength
Route of Administrati Active Ingredient/	Active Moi Ing INII: LVX8N1U	ORAL ety gredient Name		Basis of	Strength	Strength
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W	Active Moi Ing INII: LVX8N1U Its L53L36A)	ORAL ety gredient Name I733) (SUNITINIB - UNII:V99T50803M Ingredient Name		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/. SUNITINIB MALATE (U Inactive Ingredien	Active Moi Ing INII: LVX8N1U Its L53L36A)	ORAL ety gredient Name I733) (SUNITINIB - UNII:V99T50803M Ingredient Name		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S POVIDONE K25 (UNII: 1	Active Moi Ing UNII: LVX8N1U INII: LVX8N1U Its L53L36A) ODIUM (UNII: K0KQV10C35)	ORAL ety gredient Name IT73) (SUNITINIB - UNII:V99T50803M Ingredient Name M28OL1HH48)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S	Active Moi Ing UNII: LVX8N1U INII: LVX8N1U Its L53L36A) ODIUM (UNII: K0KQV10C35)	ORAL ety gredient Name IT73) (SUNITINIB - UNII:V99T50803M Ingredient Name M28OL1HH48)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S PO VIDO NE K25 (UNII: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE	Active Moi Ing INII: LVX8N1U NII: LVX8N1U NII: LVX8N1U NII: LVX8N1U NII: LVX8N1U NII: LVX8N1U NII: 26860	ORAL ety gredient Name T73) (SUNITINIB - UNII:V99T50803M Ingredient Name M280L1HH48) 7M6I30) QN327L)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S PO VIDO NE K25 (UNII: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE TITANIUM DIO XIDE (U	Active Moi Ing UNII: LVX8N1U NII: LVX8N1U tts L53L36A) ODIUM (UNII: K0KQV10C35) FE (UNII: 7009 D (UNII: 2G866 NII: 15FIX9V2J	ORAL ety gredient Name T73) (SUNITINIB - UNII:V99T50803M Ingredient Name M28OL1HH48) 7M6I30) QN327L) P)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S POVIDONE K25 (UNII: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE TITANIUM DIO XIDE (U FERRIC O XIDE RED (U)	Active Moi Ing INII: LVX8N1U NII: LVX8N1U Ats L53L36A) ODIUM (UNII: K0KQV10C35) FE (UNII: 7009 D (UNII: 2G866 NII: 15FIX9V2J NII: 15FIX9V2J	ORAL ety gredient Name T73) (SUNITINIB - UNII:V99T50803M Ingredient Name M28OL1HH48) 7M6I30) QN327L) P) 75)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S PO VIDO NE K25 (UNII: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE TITANIUM DIO XIDE (U FERRIC O XIDE RED (U)	Active Moi Ing INII: LVX8N1U NII: LVX8N1U ts L53L36A) ODIUM (UNII: K0KQV10C35) FE (UNII: 7009 D (UNII: 2G866 NII: 15FIX9F3G6 W (UNII: EX43	ORAL ety gredient Name T73) (SUNITINIB - UNII:V99T50803M Ingredient Name M280L1HH48) 7M6I30) QN327L) P) 75) 802MRT)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S POVIDONE K25 (UNII: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE TITANIUM DIO XIDE (U FERRIC O XIDE RED (U) FERRIC O XIDE YELLO	Active Moi Ing UNII: LVX8N1U NII: LVX8N1U Ats L53L36A) ODIUM (UNII: K0KQV10C35) FE (UNII: 70097 D (UNII: 2G866 NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J MII: 15FIX9V2J MII: 15FIX9V2J MII: 15FIX9V2J MII: 15FIX9V2J	ORAL ety gredient Name T73) (SUNITINIB - UNII:V99T50803M Ingredient Name M280L1HH48) 7M6I30) QN327L) P) 75) 802MRT)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S POVIDONE K25 (UNII: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE TITANIUM DIO XIDE (U FERRIC O XIDE RED (U) FERRIC O XIDE RED (U) FERRIC O XIDE YELLO FERROSOFERRIC O XI	Active Moi Ing INII: LVX8N1U NII: LVX8N1U Ats L53L36A) ODIUM (UNII: K0KQV10C35) FE (UNII: 7009 D (UNII: 2G866 NII: 15FIX9V2J NII: 15FIX9V2J NII: 1K09F3G67 W (UNII: EX43 DE (UNII: XM0 7B710)	ORAL ety gredient Name T73) (SUNITINIB - UNII:V99T50803M Ingredient Name M280L1HH48) 7M6130) 2N327L) P) 75) 802MRT) M87F357)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNI: 30W CROSCARMELLOSE S POVIDONE K25 (UNI: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE TITANIUM DIO XIDE (U FERRIC O XIDE RED (UT FERRIC O XIDE YELLO FERRIC O XIDE YELLO FERRIC O XIDE YELLO FERRIC O XIDE YELLO FERRIC O XIDE YELLO	Active Moi Ing UNII: LVX8N1U Ats L53L36A) ODIUM (UNII: K0KQV10C35) FE (UNII: 7009 D (UNII: 2G866 NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J OLUNII: 2G866 NII: 15FIX9V2J NII: 15FIX9V2J (UNII: 6DC9Q	ORAL ety gredient Name T73) (SUNITINIB - UNII: V99T50803M T03) (SUNITINIB - UNII: V99T50803M T046130) T046130) T046130) T046130) T046130) T055 802MRT) 802MRT) 167V3)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNII: 30W CROSCARMELLOSE S POVIDONE K25 (UNII: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE TITANIUM DIOXIDE (U FERRIC OXIDE RED (U) FERRIC OXIDE RED (U) FERRIC OXIDE YELLO FERROSOFERRIC OXI SHELLAC (UNII: 46N107 PROPYLENE GLYCOL SODIUM HYDROXIDE (Active Moi Ing INII: LVX8N1U NII: LVX8N1U Ats L53L36A) ODIUM (UNII: K0KQV10C35) FE (UNII: 7009 D (UNII: 2G866 NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 6DC9Q (UNII: 65X04Q6	ORAL ety gredient Name T73) (SUNITINIB - UNII: V99 T50 80 3M fungredient Name M28 OL 1HH48) M28 OL 1HH48) M28 OL 1HH48) M327L) P) 75) 8 O2MRT) M8 7F357) 167V3) C32I)		Basis of	Strength	Strength 25 mg
Route of Administrati Active Ingredient/ SUNITINIB MALATE (U Inactive Ingredien MANNITOL (UNI: 30W CROSCARMELLOSE S POVIDONE K25 (UNI: 1 MAGNESIUM STEARAT GELATIN, UNSPECIFIE TITANIUM DIO XIDE (U FERRIC O XIDE RED (UT FERRIC O XIDE YELLO FERRIC O XIDE YELLO FERRIC O XIDE YELLO FERRIC O XIDE YELLO FERRIC O XIDE YELLO	Active Moi Ing INII: LVX8N1U INII: LVX8N1U Its L53L36A) ODIUM (UNII: K0KQV10C35) FE (UNII: 7009 D (UNII: 2G86C NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J NII: 15FIX9V2J MII: 15FIX9V2J OL (UNII: 2G86C W (UNII: 2G86C INII: 15FIX9V2J INII: 15FIX9V2J MII: 15FIX9V2J INII: 15FIX9V2J MII: 15FIX9V2J INII: 15FIX9V2J MII: 15FIX	ORAL ety gredient Name T73) (SUNITINIB - UNIE V99T50803M fungredient Name fungredient Nam		Basis of	Strength	Strength 25 mg

Product Char	acte	ristics							
							score		
Shape							mm		
Flavor	F-				nt Code		r;STN;25;m	J	
Contains							.,,,,	5	
Packaging									
# Item Code			Package Description	on	Marketing	Start Date	Marketi	ng End Dat	
1 NDC:0069-077	0-38	28 in 1 BOTTL	E; Type 0: Not a Comb	ination Product	01/26/2006				
Marketing	Info	rmation							
Marketing Cate	egory	Applicatio	on Number or Monog	graph Citation	Marketing	g Start Date	Marketi	ng End Date	
NDA		NDA021938			01/26/2006				
SUTENT									
sunitinib malate	capsu	ıle							
Product Info	rmati	on							
Product Type			HUMAN PRESCRIPTIO	ON DRUG	Item Code	(Source)	NDC:00	69-0980	
Route of Admin	istrat	ion	ORAL						
Active Ingred	lie nt/	Active Moi	etv						
Active Ingree	IICIIC/		gredient Name			Basis of S	trength	Strengtl	
SUNITINIR MAI	ат е (1		773) (SUNITINIB - UNI	•V99T50803M		SUNITINIB	trengtn	50 mg	
						berninub		50 115	
Inactive Ingr	edier	nts							
			Ingredient Na	me			S	trength	
MANNITOL (UNI	I: 30W	/L53L36A)							
CROSCARMELL									
POVIDONE K25									
MAGNESIUM ST									
GELATIN, UNSP									
TITANIUM DIO X									
FERRIC OXIDE F									
FERRIC OXIDE Y									
FERROSOFERR			M87F357)						
	46 N 10	7B71O)							
SHELLAC (UNII:	401110	- /							
PROPYLENE GL	YCOL	(UNII: 6DC9Q							
	YCOL XIDE	(UNII: 6DC9Q) (UNII: 55X04Q)	C32I)						

PO TASSIUM HYDRO X	IDE (UNII: WZH	BC48M4T)					
Product Character	ristics						
	ROWN (carame	۰])	Score		no score		
	CAPSULE		Size		18 mm		
Flavor	IN OUL		Imprint Code		Pfizer;STN;	50 ·ma	
Contains			Imprint Code		FIIZE1,5 IIV,	50,mg	
Contains							
Deckeging							
Packaging				36.3.4	6 D .		
# Item Code		Package Descriptio		Marketing	Start Date	Marketii	ng End Date
1 NDC:0069-0980-38	28 in 1 BOTTL	E; Type 0: Not a Comb	ination Product	01/26/2006			
Marketing Info	rmation						
Marketing Category		on Number or Monog	raph Citation	Marketing	Start Date	Marketii	ng End Date
NDA	NDA021938			01/26/2006			0
SUTENT							
	1						
sunitinib malate capsu	lle						
Product Informati	on						
Product Type		HUMAN PRESCRIPTIO	ON DRUG	Item Code (Source)	NDC:00	69-0830
Route of Administrati	ion	ORAL					
Active Ingredient/	Activo Moi	0. t x7					
Active ingretient/		0			D • 66		
	-	redient Name			Basis of S	trength	Strength
SUNITINIB MALATE (U	JNII: LVX8N1U	173) (SUNITINIB - UNII	:V99T50803M)		SUNITINIB		37.5 mg
т., т. 1 .							
Inactive Ingredien	Its						
		Ingredient Nar	ne			St	rength
MANNITOL (UNII: 30W							
CROSCARMELLOSE S							
POVIDONE K25 (UNII:							
MAGNESIUM STEARAT	,	*					
GELATIN, UNSPECIFIE	,	,					
TITANIUM DIO XIDE (U							
FERRIC OXIDE RED (U							
FERRIC OXIDE YELLO	•						
FERROSOFERRIC OXI		M87F357)					
SHELLAC (UNII: 46 N10							
PROPYLENE GLYCOL	, -						
SO DIUM HYDRO XIDE	(UNII: 55X04Q0	C32I)					

PO	POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)							
PO	POTASSIUM HYDROXIDE (UNII: WZH3C48 M4T)							
Р	roduct Character	ristics						
С	olor	YELLOW	Score		no score			
SI	nape	CAPSULE	Size		16 mm			
Fl	avor		Imprint Code		Pfizer;STN;37;5;mg			
С	ontains							
Р	ackaging							
P #	ackaging Item Code	Package	Description	Marko	eting Start Date	Marketing End Date		
#	Item Code	0	Description Not a Combination Product	Mark 07/12/2	0	Marketing End Date		
#	Item Code	0	•		0	Marketing End Date		
#	Item Code	0	•		0	Marketing End Date		
#	Item Code NDC:0069-0830-38	28 in 1 BOTTLE; Type 0:	•		0	Marketing End Date		
#	Item Code	28 in 1 BOTTLE; Type 0:	•		0	Marketing End Date		
# 1	Item Code NDC:0069-0830-38	28 in 1 BOTTLE; Type 0:	•	07/12/2	0	Marketing End Date Marketing End Date		
# 1 N	Item Code NDC:0069-0830-38	28 in 1 BOTTLE; Type 0:	Not a Combination Product	07/12/2	0 14 seting Start Date			

Labeler - Pfizer Laboratories Div Pfizer Inc (134489525)

Establishment			
Name	Address	ID/FEI	Business Operations
Pfizer Ireland Pharmaceuticals		896090987	API MANUFACTURE(0069-0830, 0069-0980, 0069-0770, 0069-0550)

Establis	shment		
Name	Address	ID/FEI	Business Operations
Pfizer Italia S.r.l.		458521908	API MANUFACTURE(0069-0550, 0069-0770, 0069-0830, 0069-0980), MANUFACTURE(0069-0550, 0069-0770, 0069-0830, 0069-0980)

Revised: 11/2017

Pfizer Laboratories Div Pfizer Inc